A Closer Look: CDKL5 Deficiency Disorder & Rescue Treatment
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare developmental epileptic encephalopathy caused by mutations in the CDLK5 gene. The CDKL5 gene provides instructions for making proteins essential for normal brain and neuron development. When there is a deficiency disorder, a hallmark symptom is seizures beginning at approximately 3 months of life. The occurrence of seizures is unpredictable and often dangerous, increasing the risk of injury, hospitalization, and mortality, and adversely affecting a patient’s mental health, often resulting in anxiety, depression, or cognitive impairment. Both targeted treatments and rescues anti-epileptics are used to mitigate this chronic condition and improve the patient’s quality of life. This session will outline an overview of CDLK5 deficiency, with an emphasis on clinical presentation, challenges related to frequent seizures, differential diagnosis, and therapeutics behind the treatment landscape.
This session is supported by an educational grant from Neurelis.
This activity is provided by Global Education Group
After completing this activity, the participant should be better able to:
- Describe the incidence rate, etiology, and clinical presentation of CDKL5 deficiency
- Discuss the challenges imposed on the patient’s quality of life for patients who experience frequent seizure
- Review the efficacy and safety profiles of medications for seizures associated with CDKL5 deficiency disorder
- Summarize available rescue treatment for patients who suffer from frequent seizures
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring for a maximum of .25 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation
This educational activity for .25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for .25 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-0000-22-362-H01-P)
This is a knowledge-based activity.
This activity was released on 12/15/2022 and is valid for one year. Requests for credit must be made no later than 12/15/2023.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete and pass the posttest with a score of at least 70% and complete the evaluation/application for credit. Certificates will then be available for download. Pharmacists: Credit will be awarded via CPE Monitor 60 days post the enduring meeting
Fee & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter
Reported Financial Relationship
Consulting Fee: Zogenix Pharmaceauticals
Contracted Research: Zogenix Pharmaceuticals, Marinus Pharmaceauticals
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 ACCME (All Other)
- 0.25 ACCME (MD/DO Only)
- 0.25 ACPE Pharmacy
- 0.25 ANCC